Targeting KRAS in cancer

nature cancer
2/2/22, 11:00 AM
America/Pacific Time UTC -8:00 / -7:00

Description

This webinar discusses the progress in targeting KRAS, as well as the preclinical platforms and technologies that further our understanding of KRAS biology in tumors.

 

We will provide an overview of KRAS biology in cancer and recent therapeutic developments for patients with KRAS-mutated tumors. Chiara Ambrogio (University of Torino, Italy) and Julian Downward (Francis Crick Institute, UK) will discuss the different preclinical platforms and the technological advances that have enabled a deep understanding of the inner workings of KRAS in cancer, as well as the development of specific and potent KRAS inhibitors that led to the recent FDA approval of sotorasib for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. Our speakers will present their different points of view on the topic, which will be followed by a Q&A session chaired by Miguel Foronda, Senior Editor at Nature Cancer (New York, US).

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Targeting KRAS in cancer

Inglês

 

Speakers

Julian Downward, Chiara Ambrogio, Miguel Foronda